Skip to main content

Published

Nirmatrelvir–ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.
Baden LR. The Lancet Infectious Diseases 2026;:https://doi.org/10.1016/S1473-3099(26)00406-8.
[A double-blind randomised trial of 959 adults with long COVID found that 15 or 25 days of nirmatrelvir-ritonavir provided no significant benefit over placebo for cognitive, autonomic or exercise-related symptoms at 90 days. No improvements were found in secondary outcomes and no safety concerns emerged. Findings indicate that extended antiviral treatment does not improve these long COVID symptom patterns, highlighting the need for alternative treatments.]
Available with an NHS OpenAthens password

Age Groups
Adults
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Community Clinics
General Practice
Staff Groups
Drug Therapy
Medic